Menu Search
Equities

Getinge AB

GETI B:STO

Getinge AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)194.30
  • Today's Change3.45 / 1.81%
  • Shares traded1.02m
  • 1 Year change-7.12%
  • Beta0.6074
Data delayed at least 15 minutes, as of Nov 08 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform1
Hold5
Sell2
Strong Sell0

Share price forecast in SEK

The 8 analysts offering 12 month price targets for Getinge AB have a median target of 236.50, with a high estimate of 300.00 and a low estimate of 180.00. The median estimate represents a 21.72% increase from the last price of 194.30.
High54.4%300.00
Med21.7%236.50
Low-7.4%180.00

Dividends in SEK

In 2023, Getinge AB reported a dividend of 4.40 SEK, which represents a 3.53% increase over last year. The 10 analysts covering the company expect dividends of 4.46 SEK for the upcoming fiscal year, an increase of 1.43%.
Div growth (TTM)3.53%
More ▼

Earnings history & estimates in SEK

On Oct 18, 2024, Getinge AB reported 3rd quarter 2024 earnings of 2.24 per share. This result was in line with the consensus of the 3 analysts following the company and under-performed last year's 3rd quarter results by 15.79%.
The next earnings announcement is expected on Jan 28, 2025.
Average growth rate-1.06%
Getinge AB reported annual 2023 earnings of 9.19 per share on Feb 01, 2024.
Average growth rate+15.98%
More ▼

Revenue history & estimates in SEK

Getinge AB had 3rd quarter 2024 revenues of 7.87bn. This missed the 8.09bn consensus estimate of the 5 analysts following the company. This was 10.21% above the prior year's 3rd quarter results.
Average growth rate+2.84%
Getinge AB had revenues for the full year 2023 of 31.83bn. This was 12.49% above the prior year's results.
Average growth rate+5.02%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.